0001666690-18-000004.txt : 20180212 0001666690-18-000004.hdr.sgml : 20180212 20180212135755 ACCESSION NUMBER: 0001666690-18-000004 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180212 DATE AS OF CHANGE: 20180212 EFFECTIVENESS DATE: 20180212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IB Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001666690 IRS NUMBER: 462638163 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-305387 FILM NUMBER: 18595616 BUSINESS ADDRESS: STREET 1: 8480 HONEYCUTT ROAD STREET 2: SUITE 120 CITY: RALEIGH STATE: NC ZIP: 27615 BUSINESS PHONE: 919-275-1933 MAIL ADDRESS: STREET 1: 8480 HONEYCUTT ROAD STREET 2: SUITE 120 CITY: RALEIGH STATE: NC ZIP: 27615 FORMER COMPANY: FORMER CONFORMED NAME: Innovate Biopharmaceuticals Inc. DATE OF NAME CHANGE: 20160211 D 1 primary_doc.xml X0708 D LIVE 0001666690 IB Pharmaceuticals Inc. 8480 HONEYCUTT ROAD SUITE 120 RALEIGH NC NORTH CAROLINA 27615 919-275-1933 DELAWARE Innovate Biopharmaceuticals Inc. Corporation true 2014 Jay Madan c/o IB Pharmaceuticals Inc. 8480 Honeycutt Road, Suite 120 Raleigh NC NORTH CAROLINA 27615 Executive Officer Director Sandeep Laumas c/o IB Pharmaceuticals Inc. 8480 Honeycutt Road, Suite 120 Raleigh NC NORTH CAROLINA 27615 Executive Officer Director Christopher Prior c/o IB Pharmaceuticals Inc. 8480 Honeycutt Road, Suite 120 Raleigh NC NORTH CAROLINA 27615 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2018-01-29 false true true true false 0 H.C. Wainwright & Co., LLC 375 H.C. Wainwright & Co., LLC 375 430 Park Avenue 4th Floor New York NY NEW YORK 10022 CA CALIFORNIA FL FLORIDA IL ILLINOIS MA MASSACHUSETTS NJ NEW JERSEY NY NEW YORK false GP Nurmenkari Inc. 153480 GP Nurmenkari Inc. 153480 64 Wall Street Suite 402 Norwalk CT CONNECTICUT 06850 AL ALABAMA AZ ARIZONA CA CALIFORNIA CO COLORADO CT CONNECTICUT FL FLORIDA GA GEORGIA MD MARYLAND MA MASSACHUSETTS NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA OH OHIO PA PENNSYLVANIA TX TEXAS WI WISCONSIN false 36316200 32751768 3564432 $18,132,660.18 in new money; $9,229,819.40 conversion of debt; $5,389,288.44 upon exercise of warrants false 168 0 1535284 true 0 false IB Pharmaceuticals Inc. /s/ Jay Madan Jay Madan President 2018-02-12